Prescribing Information
Composition:
Dasanix50 : Each tablet contains Dasatinib50 mg
Clinical Pharmacology:
Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the “Philadelphia chromosome”) and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML)and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.